Prognosis is a horizon scanning service that monitors emerging health technologies as they go through clinical trial development and the regulatory approval process.
I am looking for…
View a sampling of our Prognosis reports.
Nerivio Migra provides neuromodulation therapy through a noninvasive, wearable device. The Nerivio Migra system consists of a pair of electrodes mounted on an armband with a power source. The wireless device is self-applied to the upper arm, and delivers transcutaneous electrical nerve stimulation that is believed to interrupt pain signals traveling to the brain.
OTX-TP is an eye insert that delivers travoprost to the ocular surface for up to 90 days. It is proposed as an alternative to daily eye drops for lowering intraocular pressure in patients with glaucoma or ocular hypertension.
Pexidartinib is an oral small molecule inhibitor of colony stimulating factor-1 receptor (CSF1R) for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations, and which is not amenable to improvement with surgery.
Entrectinib (RXDX-101) is an oral tumor-agnostic agent intended to selectively inhibit the tyrosine kinase activity of TRKA, TRKB, TRKC, and ROS1 rearrangements. Entrectinib is proposed to treat NTRK gene fusion-positive solid tumors as well as ROS1-positive locally advanced or metastatic non-small cell lung cancer.
Ruzurgi (amifampridine, base form) is an oral drug intended for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in children aged 6 to < 17 years. Ruzurgi is a voltage-gated potassium channel inhibitor that prolongs the depolarization of the pre-synaptic cell membrane, allowing for enhanced calcium influx into the neuron. This facilitates increased release of acetylcholine and improves neuromuscular transmission.